IB maintains two principal subsidiaries:
In March 2018, IB acquired Imaging Biometrics, LLC, a Wisconsin USA-based healthcare imaging software company. Imaging Biometrics supplies medical technology solutions and has a strong neuroimaging product portfolio, anchored by its IB Neuro™ MRI and CT image analysis software. Find out more at the Imaging Biometrics website: imagingbiometrics.com.
And in October 2025, IB acquired Kirkstall Limited, the developer of the Quasi-Vivo® organ-on-a-chip platform for pharmaceutical research, toxicology, and disease modelling. See the Kirkstall website for more information: kirkstall.com.
See all IB News on the London Stock Exchange (LSE) Regulatory News Service (RNS)
Imaging Biometrics Ltd ordinary shares are traded on the Standard List of the London Stock Exchange under ticker code IBAI
There are no restrictions on the transfer of shares.
As at 24 March 2025, as far as the Directors are aware, the following shareholders
are interested in 3% or more of the issued share capital of the Company.
Total shares in issue: 246,709,789 Ordinary Shares of £0.01 each
investor@imagingbiometrics.com
Imaging Biometrics Ltd
IFC 5
St Helier, Jersey, Channel Islands
JE1 1ST
Imaging Biometrics Ltd is a Jersey Registered Public Company #2044